Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 191,000 shares of common stock to two newly hired employees on June 1, 2026.
The options, issued under the 2022 Employment Inducement Incentive Award Plan, have a $3.98 exercise price, 10-year term, and four-year vesting schedule.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ZNTL
-0.75%
7 alerts
-0.75%Session close to close
$269.08MMarket Cap
0.1xRel. Volume
In the Jun 2 session, ZNTL declined 0.75%, reflecting a mild negative market reaction.
Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
This announcement details standard inducement equity grants—191,000 non-qualified stock options at a...
Analysis
This announcement details standard inducement equity grants—191,000 non-qualified stock options at an exercise price of $3.98 with a 10‑year term and four-year vesting—to two new hires under the 2022 Inducement Plan. It follows recent governance, clinical, and financial updates as Zentalis advances azenosertib through Phase 2 and Phase 3 programs. Investors may watch how ongoing leadership expansion, option-based compensation, and upcoming DENALI and ASPENOVA milestones interact with cash resources and future disclosures.
Key Figures
Inducement options granted:191,000 sharesNew hires:2 employeesExercise price:$3.98 per share+5 more
8 metrics
Inducement options granted191,000 sharesNon-qualified stock options to two newly hired employees
New hires2 employeesRecipients of 2022 Employment Inducement Plan grants
Exercise price$3.98 per shareEqual to Nasdaq closing price on June 1, 2026
Option term10 yearsTerm of inducement stock options
Initial vesting25%Vests on first anniversary of vesting commencement date
Remainder vesting75% over three yearsVests in equal monthly installments thereafter
Current share price$3.98Price used as exercise price and latest close before news
Price change 24h-1.23%Move prior to or into this administrative announcement
First patient dosed in ASPENOVA Phase 3 trial for Cyclin E1-positive PROC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has produced mixed reactions: clinical and trial progress sometimes align positively, while conference and data updates have also seen negative or flat responses.
Recent Company History
Over the past months, Zentalis has focused on advancing azenosertib and building its commercial and governance structure. Key milestones include first patient dosed in the Phase 3 ASPENOVA trial (May 5, 2026), Q1 2026 financials showing a net loss of $35.4 million with cash of $211.8 million, and encouraging Phase 1b MUIR data. Board and leadership enhancements on May 27, 2026 supported commercialization readiness. Today’s inducement option grants fit into this broader pattern of scaling the organization around late-stage development.
"granted non-qualified stock options to purchase an aggregate of 191,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The stock options have an exercise price of $3.98 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"will vest over four years, with 25% of the options vesting on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement planfinancial
"under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $3.98 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
What stock options did Zentalis (ZNTL) grant on June 1, 2026?
Zentalis granted non-qualified stock options for an aggregate of 191,000 common shares to two new employees. According to Zentalis, these options were issued under the 2022 Employment Inducement Incentive Award Plan as material inducements to the employees’ hiring.
What is the exercise price of the new Zentalis (ZNTL) inducement stock options?
The exercise price of the new Zentalis inducement stock options is $3.98 per share. According to Zentalis, this price equals the closing price of its common stock on the Nasdaq Global Market on the June 1, 2026 grant date.
How do the Zentalis (ZNTL) inducement stock options vest for the new employees?
The Zentalis inducement stock options vest over four years, subject to continued service. According to Zentalis, 25% vests on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next three years.
What is the term of the Zentalis (ZNTL) inducement stock options granted in June 2026?
The inducement stock options granted by Zentalis have a 10-year term from the grant date. According to Zentalis, the options were issued on June 1, 2026 and remain exercisable for ten years, subject to vesting and continued employment conditions.
Under which plan were the June 2026 Zentalis (ZNTL) inducement options granted?
The June 2026 inducement options were granted under the 2022 Employment Inducement Incentive Award Plan. According to Zentalis, this plan is used exclusively for equity awards to new hires or rehires as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
How many employees received Zentalis (ZNTL) inducement stock options on June 1, 2026?
Two newly hired employees received the Zentalis inducement stock options on June 1, 2026. According to Zentalis, these employees were granted non-qualified options covering a total of 191,000 common shares as inducement awards tied to their employment.
